BARDA Selects Edesa Biotech's Paridiprubart For U.S. Funded Platform Trial In General ARDS
Portfolio Pulse from Benzinga Newsdesk
Edesa Biotech's drug candidate, paridiprubart (EB05), has been selected by BARDA for a U.S. government-funded Phase 2 clinical trial to evaluate its effectiveness in treating acute respiratory distress syndrome (ARDS). This project will complement Edesa's ongoing COVID-19 ARDS drug development.
June 24, 2024 | 12:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Edesa Biotech's paridiprubart (EB05) has been selected by BARDA for a U.S. government-funded Phase 2 clinical trial to evaluate its effectiveness in treating ARDS. This selection is expected to complement Edesa's ongoing COVID-19 ARDS drug development efforts.
The selection of paridiprubart by BARDA for a government-funded trial is a significant milestone for Edesa Biotech. It not only validates the potential of their drug candidate but also provides financial support and increased visibility. This is likely to positively impact Edesa's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100